Vital Signs - Unleashing a Storm? Effect of warfarin label update on pharmacogenetics testing

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on February 26, 2007, provides a strategic overview of the potential impact of changes to the warfarin drug label on pharmacogenetic testing. Additionally, an emerging company profile is provided for Tm Bioscience Corporation, a clinical diagnostics company involved in manufacturing and marketing genetic tests. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of February 12 - February 16, 2007.

Table of Contents

Vital Signs - Unleashing a Storm? Effect of warfarin label update on pharmacogenetics testingVital Signs: 26 February 2007This week's issue:




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 20-Nov-17

Region : North America

Release Date : 07-Nov-17

Region : North America

Release Date : 06-Nov-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.